

Presentation

Inactivated vaccine containing per dose of 2 ml 1.80 microgram *Pasteurella multocida* dermonecrotic toxin (as toxoid) and 45 mg inactivated *Bordetella bronchiseptica* cells. Also contains liquid paraffin, Polysorbate 80 and sorbitan monooleate as adjuvant.

Uses

For vaccination of sows and gilts to reduce infection and clinical signs of atrophic rhinitis caused by *Bordetella bronchiseptica* and *Pasteurella multocida* in their progeny. Protection has been demonstrated in the progeny of sows and gilts vaccinated during pregnancy.

Dosage and administration

Sows at any age or weight and gilts from an age of 18 weeks: 2 ml by deep intramuscular injection behind the ear. The use of a 16g x 1½" hypodermic needle is recommended.

Gilts and sows, which have not been vaccinated with the vaccine before should be given a primary, followed 6 weeks later by a second vaccination. No further vaccination is needed for a period of 3 months after the second vaccination. Sows should then be revaccinated once for each subsequent pregnancy, with the interval between vaccination and farrowing not exceeding 150 days. Where possible, these vaccinations should take place 2-6 weeks before farrowing, but to minimise handling, e.g. in outdoor units and loose housed sow accommodation, sows may be vaccinated at weaning, service or pregnancy testing.

Pigs newly introduced into the farm, not previously vaccinated, should be given the basic vaccination immediately.

Maximum benefit from vaccination with this product will not be obtained unless appropriate attention is paid to animal management, housing conditions and ventilation. Veterinary advice should be sought prior to the start of a vaccination programme.

A good immune response is reliant on the reaction of an immunogenic agent and fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immunocompetence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.

Contra-indications, warnings, etc

Do not vaccinate unhealthy animals.

After vaccination mild, transient clinical reactions (fever, decreased liveliness) may occur on the first day after vaccination. For some weeks after vaccination a swelling may be present at the site of injection. Local tissue reactions in the form of abscesses occur. At 6 weeks after vaccination these local reactions are considerably decreased.

No adverse reactions other than already mentioned above have been observed after administration of a double dose.

Can be used during pregnancy.

In common with all interference with sows during the last 2 weeks of gestation, vaccination at that time could incur a risk to the sow and her litter and so is best avoided.

Allow vaccine to reach ambient temperature (between +15 and +25°C) before use. Shake vigorously before and during use. Ensure that vaccination equipment is clean and sterile before use and that it is kept so during vaccination.

No information is available on the safety and efficacy from the concurrent use of this vaccine with any other. It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with the product.

Do not mix with any other medicinal products.

Operator warnings

To the user:

This product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.

If you are accidentally injected with this product, seek prompt medical advice, even if only a

very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of the finger pulp or tendon.

Withdrawal period

Zero days.

For animal treatment only. Keep out of reach and sight of children.

Pharmaceutical precautions

Store between +2°C and +8°C. Keep container in the outer carton. Do not freeze.

Shelf life after first opening: 3 hours.

Disposal advice

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.

Legal category

POM-VPS

Packaging Quantities

Cardboard box containing one 50 ml multi-dose vial of hydrolytic Type II glass or polyethylene terephthalate (PET), closed with a nitril rubber stopper and sealed with a colour-coded aluminium cap.

Marketing authorisation number

Vm 01708/4303.